VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
1.800
-0.060 (-3.23%)
At close: Mar 13, 2026, 4:00 PM EDT
1.814
+0.014 (0.78%)
After-hours: Mar 13, 2026, 7:55 PM EDT
VivoSim Labs Employees
VivoSim Labs had 14 employees as of December 31, 2025. The number of employees did not change compared to the same quarter last year.
Employees
14
Change
n/a
Growth
n/a
Revenue / Employee
$10,143
Profits / Employee
-$87,643
Market Cap
4.69M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | 0 | - | 14 | 0 |
| Sep 30, 2025 | 13 | -6 | -31.58% | 13 | 0 |
| Jun 30, 2025 | 13 | -7 | -35.00% | 13 | 0 |
| Mar 31, 2025 | 13 | -7 | -35.00% | 5 | 8 |
| Dec 31, 2024 | 14 | -4 | -22.22% | 14 | 0 |
| Sep 30, 2024 | 19 | -4 | -17.39% | 19 | 0 |
| Jun 30, 2024 | 20 | -3 | -13.04% | 20 | 0 |
| Mar 31, 2024 | 20 | -4 | -16.67% | 12 | 8 |
| Dec 31, 2023 | 18 | -2 | -10.00% | 18 | 0 |
| Sep 30, 2023 | 23 | 3 | 15.00% | 23 | 0 |
| Jun 30, 2023 | 23 | 4 | 21.05% | 23 | 0 |
| Mar 31, 2023 | 24 | 6 | 33.33% | 15 | 9 |
| Dec 31, 2022 | 20 | 8 | 66.67% | 20 | 0 |
| Sep 30, 2022 | 20 | 9 | 81.82% | 20 | 0 |
| Jun 30, 2022 | 19 | 10 | 111.11% | 19 | 0 |
| Mar 31, 2022 | 18 | 9 | 100.00% | 9 | 9 |
| Dec 31, 2021 | 12 | 5 | 71.43% | 12 | 0 |
| Sep 30, 2021 | 11 | 5 | 83.33% | 11 | 0 |
| Jun 30, 2021 | 9 | 3 | 50.00% | 9 | 0 |
| Mar 31, 2021 | 9 | 3 | 50.00% | 4 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aptevo Therapeutics | 37 |
| Lunai Bioworks | 29 |
| GeoVax Labs | 17 |
| Genprex | 13 |
| Revelation Biosciences | 9 |
| MetaVia | 9 |
| Aprea Therapeutics | 8 |
| Galmed Pharmaceuticals | 6 |
VIVS News
- 11 days ago - VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales - GlobeNewsWire
- 4 weeks ago - VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego - GlobeNewsWire
- 6 weeks ago - VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China - GlobeNewsWire
- 2 months ago - VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer - GlobeNewsWire
- 7 months ago - VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer - GlobeNewsWire
- 10 months ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 10 months ago - VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference - GlobeNewsWire
- 11 months ago - VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference - GlobeNewsWire